Influenza Clinical Trial
Official title:
Clinical Study to Assess Efficacy, Safety, Tolerability and Optimal Dose Ranging of XC8 in Doses 20, 100 and 200 mg Once Daily in Patients With Uncomplicated Influenza or Other Acute Respiratory Viral Infections (ARVI)
A multicenter double-blind, randomized, placebo-controlled, parallel-group comparative Phase
II / III clinical study to assess safety, tolerability, efficacy and optimal dose ranging of
XC8 vs. placebo in patients with uncomplicated influenza or other ARVI during a 5-day
treatment.
The primary objective of the study was to demonstrate the difference in time before the onset
of a sustained improvement in clinical symptoms according to the Severity Rating Scale for
ARVI, and to determine the optimal dose of XC8 in the treatment of influenza and other ARVI.
Twenty-three Russian centers were approved for participation in this study. Twenty centers
were initiated. Patients were enrolled in 18 centers. The study consisted of two parts: phase
II and phase III. Each of the parts included 3 periods: screening, treatment, follow-up.
In the first part of the study (Phase II), all eligible patients were randomized into 4
groups (groups A, B, C, and D) in a 1:1:1:1 ratio:
Group A - XC8 20 mg daily (40 patients); Group B - XC8 100 mg daily (40 patients); Group C -
XC8 200 mg daily (40 patients); Group D - placebo (40 patients).
Interim analysis was planned after the end of the first part of the study (Phase II). Based
on the results of the interim analysis, the most promising XC8 dose group was selected and
the necessary set was calculated to compare this group with the placebo group by the primary
endpoint in a pooled set using an adaptive design with type I error control.
In the second part of the study (Phase III), all eligible patients were randomized into 2
groups (groups C and D) in a 1:1 ratio:
Group C - XC8 200 mg daily (80 patients); Group D - placebo (80 Patients).
During the treatment period (5 days), patients received XC8 / placebo daily on a background
of standard symptomatic therapy. The follow-up period lasted for 9 days.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
| Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
| Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
| Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
| Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
| Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
| Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
| Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
| Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
| Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
| Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
| Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
| Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
| Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
| Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
| Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
| Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
| Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
| Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
| Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |